Full-Time

Senior Director

Delegate Oversight

Updated on 9/3/2026

Alignment-Health

Alignment-Health

1,001-5,000 employees

Medicare Advantage plans with on-demand care

Compensation Overview

$130.3k - $195.5k/yr

Remote in USA

Remote

Bachelor's, Master's

Category
Risk & Compliance (1)
Required Skills
Six Sigma
Data Analysis

Get referred to Alignment-Health

See people who can refer or advise you

Requirements
  • 10–12+ years of experience in healthcare operations, delegated oversight, provider network management, or value-based care.
  • 5+ years of leadership with delegated oversight specifically, compliance, or provider performance.
  • 5+ years of leadership experience with accountability for performance outcomes.
  • Experience developing and executing performance management strategies across clinical, operational, and compliance domains.
  • Demonstrated ability to influence senior stakeholders and manage external partner relationships.
  • Strong understanding of healthcare regulatory frameworks, including CMS, DMHC, DHCS, and NCQA, and delegated models.
  • Experience working in matrixed organizations and driving cross-functional initiatives.
  • A bachelor's degree is required in Healthcare Administration, Public Health, Business Administration, Nursing, or a related field.
  • Strong strategic thinking with the ability to translate strategy into execution.
  • An analytical mindset with experience using data to drive decisions and performance improvement.
  • Excellent communication and stakeholder management skills.
  • Ability to manage ambiguity and balance multiple priorities.
  • A collaborative leadership style with the ability to influence without authority.
Responsibilities
  • Own and evolve the enterprise delegated oversight strategy, ensuring alignment with corporate objectives, regulatory requirements, and value-based care priorities.
  • Establish a holistic performance framework integrating clinical, operational, financial, and compliance metrics across all delegated entities.
  • Maintain accountability for delegated performance outcomes, including quality, utilization, risk adjustment, member experience, and cost of care.
  • Ensure oversight models are scalable and adaptable to support organizational growth and increasing complexity in risk-bearing arrangements.
  • Define and lead enterprise governance structures that proactively identify, assess, and mitigate risks across the delegated network.
  • Oversee risk stratification methodologies, performance scoring, and audit frameworks to ensure consistency, rigor, and regulatory alignment.
  • Act as the senior escalation point for performance and compliance risks, ensuring timely intervention and resolution of issues with enterprise impact.
  • Provide regular, transparent reporting to executive leadership on delegated performance, risks, and mitigation strategies.
  • Serve as the lead relationship owner for delegated partner executives, driving alignment on performance expectations and long-term strategy.
  • Facilitate executive-level performance reviews with IPAs and MSOs, ensuring accountability and measurable improvement.
  • Influence internal executive stakeholders by translating performance insights into strategic recommendations and action plans.
  • Represent delegated oversight in enterprise initiatives, regulatory readiness efforts, and cross-functional planning.
  • Drive the evolution of delegated oversight into a proactive, insight-driven function, leveraging analytics to identify opportunities and intervene early.
  • Lead cross-functional collaboration with Clinical, Quality, Compliance, Network, and Operations teams to improve delegated outcomes.
  • Promote standardization, best practice sharing, and continuous improvement across the delegated network.
  • Ensure tools, reporting, and processes enable effective performance management and decision-making.
  • Lead and develop a high-performing team, setting clear expectations and fostering a culture of accountability and continuous improvement.
  • Provide direction and oversight across analytics, audit, and performance management activities within the function.
  • Influence and align matrixed teams to drive enterprise performance goals.
  • Provide direct oversight of team members supporting delegated oversight, including performance, audit, and analytics functions, and provide matrix leadership across cross-functional stakeholders involved in delegated performance.
Desired Qualifications
  • A master's degree is strongly preferred, such as MHA, MPH, MBA, or MSN, with a focus in healthcare management, policy, or operations.
  • Advanced training or certification in value-based care, population health, healthcare compliance, or project management is a plus.
  • Lean/Six Sigma training is preferred.

Alignment Health delivers Medicare Advantage plans for seniors, offering 24/7 access to healthcare through in-person, in-home, or telehealth options. Plans are funded by premiums paid by Medicare beneficiaries and federal reimbursements, with a focus on coordinated care supported by provider-facing technology to improve delivery and efficiency. Differentiation comes from pairing high-touch, VIP-level service with affordable pricing and technology-driven care coordination. The overarching goal is to simplify and enhance the healthcare experience for seniors by providing accessible, high-quality care without excessive costs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Orange, California

Founded

2013

Get referred to Alignment-Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026 revenue hit $1.336 billion, up 31.6%, beating guidance.
  • Adjusted EBITDA reached $68.1 million, and management raised 2026 membership and profitability guidance.
  • Citibank’s $200 million credit facility, signed February 26, 2026, funds acquisitions through 2029.

What critics are saying

  • July 2026 whistleblower allegations accuse Alignment of misclassifying $8-10 million expenses as capex.
  • Multiple law firms opened securities investigations after the July 8, 2026 stock drop.
  • A restatement or CMS scrutiny would crush investor trust and threaten ALHC’s refinancing access.

What makes Alignment-Health unique

  • Alignment’s 45-market Medicare Advantage footprint reached 294,100 members by June 30, 2026.
  • AVA AI stratifies members using real-time clinical data, targeting high-risk admissions within 30 days.
  • Dawn Maroney leads acquisitions, product strategy, and market expansion across senior-care operations.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
Market Wire News
Aug 20th, 2026
Alignment Healthcare to present in Baird 2026 Global Healthcare Conference and attend Morgan Stanley 24th Annual Global Healthcare Conference.

Alignment Healthcare to present in Baird 2026 Global Healthcare Conference and attend Morgan Stanley 24th Annual Global Healthcare Conference. MWN-AI** Summary. Alignment Healthcare, Inc. (NASDAQ: ALHC), a pioneer in transformative senior care, is gearing up for two key healthcare conferences in New York this September. The company will present at the Baird 2026 Global Healthcare Conference during a fireside chat on Tuesday, September 15, at 12:50 p.m. EDT. Following this, Alignment will also attend the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16. Investors and interested parties can access a webcast and replay of the Baird presentation on Alignment's investor relations website. Founded in California, Alignment Healthcare focuses on empowering its Medicare Advantage members to achieve vibrant, healthful aging through a consumer-focused approach. The organization's mission is to provide high-quality and low-cost healthcare options, which they realize through partnerships with trusted local providers and a customized care model. Their approach includes a dedicated 24/7 concierge care team and the innovative AVA(R) technology platform, which streamlines care coordination. As the company continues to expand its services and enhance its national presence, Alignment Healthcare remains committed to its core values of service and prioritizing the needs of seniors. With an emphasis on tailored care, Alignment is positioned to meet the growing healthcare demands of an aging population in the U.S. For additional information and updates, stakeholders are encouraged to visit Alignment Healthcare's website. The company's active participation in these significant conferences underscores its dedication to fostering dialogues that promote better healthcare solutions while also positioning itself as a thought leader in the industry. MWN-AI** Analysis. Alignment Healthcare, Inc. (NASDAQ: ALHC) is poised to strengthen its market positioning following its participation in significant healthcare conferences, specifically the Baird 2026 Global Healthcare Conference on September 15 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. Investors should keep an eye on these events as they present crucial opportunities for the company to articulate its growth strategy and showcase its innovative care model tailored for Medicare Advantage members. The focus of Alignment Healthcare on providing high-quality, low-cost care through innovative technology and strong partnerships with local providers sets it apart in the competitive healthcare landscape. The unique, consumer-driven approach, signified by its technology platform, AVA(R), facilitates 24/7 concierge care, which is increasingly appealing to an aging population. This strategic positioning aligns with the growing demand for efficient, personalized healthcare solutions, making Alignment a noteworthy player in this space. Given its core mission of prioritizing seniors and the strong emphasis on customer service, the upcoming presentations will likely delve into how Alignment intends to expand its national footprint. Attendance at two prominent conferences not only enhances visibility but also positions the company to attract potential investors interested in the burgeoning Medicare Advantage market. As the market shifts towards value-based care, Alignment's emphasis on coordinated care models may resonate well with investors looking for stable growth in the healthcare sector. It is advisable for shareholders and prospective investors to monitor developments from these presentations closely. Positive insights or strategic announcements could catalyze stock performance, making ALHC a candidate for investors targeting the health care sector's growth trajectory. In summary, Alignment Healthcare's upcoming participation in these conferences represents a pivotal moment for visibility and investor engagement, with the potential for fostering growth and shareholder value long-term. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. August 20, 2026 08:00:00 am ORANGE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) - Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will participate in and attend two upcoming healthcare conferences in New York: * Presenting: Baird 2026 Global Healthcare Conference: Fireside chat and presentation on Tuesday, Sept. 15, at 12:50 p.m. EDT * Attending: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, Sept. 16. A webcast and replay of the Baird presentation will be available on Alignment's investor relations website at https://ir.alignmenthealth.com/. About Alignment Healthcare Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA(R). As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com. FAQ**. How does Alignment Healthcare Inc. (ALHC) plan to leverage its participation in key conferences to enhance investor relations and market visibility? Alignment Healthcare Inc. (ALHC) plans to leverage its participation in key conferences by showcasing its innovative healthcare models, sharing strategic updates, and engaging directly with investors to enhance its market visibility and strengthen investor relations. What new initiatives is Alignment Healthcare Inc. (ALHC) presenting at the upcoming Baird and Morgan Stanley conferences to improve senior care? I'm unable to provide real-time updates or information on initiatives for Alignment Healthcare Inc. (ALHC) at the upcoming Baird and Morgan Stanley conferences as my training only covers data until October 2023, and I don't have access to current events or projections. Can Alignment Healthcare Inc. (ALHC) provide insights into its growth strategy and expansion plans discussed during the Baird conference? Alignment Healthcare Inc. (ALHC) has articulated a robust growth strategy emphasizing market expansion through innovative healthcare models and collaborations, as discussed during the Baird conference, highlighting its commitment to increasing service reach and improving patient outcomes. What technology advancements, specifically AVA(R), will Alignment Healthcare Inc. (ALHC) highlight during its presentations at the upcoming healthcare conferences? Alignment Healthcare Inc. (ALHC) will showcase advancements in their AVA(R) technology, emphasizing its role in enhancing data analytics, streamlining patient engagement, and improving care coordination during upcoming healthcare conferences. **MWN-AI FAQ is based on asking OpenAI questions about Alignment Healthcare Inc. (NASDAQ: ALHC).

Becker's Payer Issues
Aug 11th, 2026
Alignment Health secures $200M credit line to fund plan acquisitions

Alignment Health, a Medicare Advantage insurer, has secured a $200 million credit line from Citibank to fund potential acquisitions and market expansion. The three-year credit facility, established on 26 February, will support purchases of healthcare delivery groups, standalone and provider-sponsored MA plans, and other risk-bearing assets in targeted geographies. As of 30 June, the company had not drawn on the credit line. Alignment currently operates in 45 markets with 294,100 health plan members. The insurer previously outlined a similar acquisition strategy in its 2021 initial public offering filing. Its last acquisition was California's Citizens Choice Health Plan in 2014, which rebranded as Alignment Health Plan the following year.

MarketBeat
Jul 30th, 2026
Alignment Healthcare (NASDAQ:ALHC) posts earnings results, beats estimates by $0.04 EPS.

Alignment Healthcare (NASDAQ:ALHC) posts earnings results, beats estimates by $0.04 EPS. July 30, 2026 Key points. * Alignment Healthcare exceeded second-quarter expectations, reporting $0.17 in EPS versus the $0.13 consensus and $1.34 billion in revenue versus $1.31 billion expected. * Membership grew 31% year over year to 294,100, while adjusted EBITDA rose 48% to $68 million. Management raised its 2026 membership and guidance outlook and sees approximately $880 million in embedded adjusted gross profit potential. * Near-term risks include seasonally weaker third-quarter profitability, higher-acuity members and increased investments. Separate law-firm investigations into potential securities-law violations add legal and investor uncertainty, though they do not establish wrongdoing. * Five stocks we like better than Alignment Healthcare. Alignment Healthcare (NASDAQ:ALHC - Get Free Report) issued its earnings results on Thursday. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.04, FiscalAI reports. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The firm had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. Here are the key takeaways from Alignment Healthcare's conference call: * Strong second-quarter results: Membership rose 31% year over year to 294,100, revenue increased 32% to $1.3 billion, and adjusted EBITDA grew 48% to $68 million, with a 60-basis-point margin expansion. * Alignment raised its 2026 membership and revenue outlook, increased the low end of its adjusted gross profit guidance by $10 million and adjusted EBITDA guidance by $7 million, and remains on track for its full-year targets. * Management estimates approximately $880 million of embedded adjusted gross profit potential in its current membership base, as roughly half of members remain in their first or second year and are expected to become more profitable as clinical programs mature. * The latest AVA AI stratification model can identify the 10% of members expected to account for nearly 70% of hospital admissions over the following 30 days, supporting more targeted intervention by Care Anywhere teams. * Third-quarter profitability is expected to be seasonally weaker, with only about 30% of full-year adjusted EBITDA projected in the second half; higher-acuity new members, Part D trends, and additional clinical, AI, automation, hiring, and market-preparation investments are expected to pressure MBR and SG&A. Alignment Healthcare price performance. Shares of Alignment Healthcare stock traded up $0.32 during trading on Thursday, hitting $18.61. The stock had a trading volume of 4,016,545 shares, compared to its average volume of 4,371,387. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.56. Alignment Healthcare has a 12 month low of $12.91 and a 12 month high of $25.12. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 206.78, a P/E/G ratio of 2.49 and a beta of 1.05. The business's 50-day moving average is $19.69 and its 200 day moving average is $19.81. Key headlines impacting Alignment Healthcare. Here are the key news stories impacting Alignment Healthcare this week: * Positive Sentiment: Alignment Healthcare reported second-quarter EPS of $0.17, exceeding the $0.13 analyst consensus, while revenue of $1.34 billion surpassed expectations of $1.31 billion. Management said results exceeded the high end of guidance across key metrics. Alignment Healthcare Reports Second Quarter 2026 Results * Positive Sentiment: The earnings beat provides a favorable near-term catalyst, supported by a reported 11.50% return on equity and a 0.47% net margin, although profitability remains modest. * Neutral Sentiment: Alignment Healthcare maintained third-quarter revenue guidance of approximately $1.3 billion, in line with consensus estimates. Full-year 2026 revenue guidance of approximately $5.2 billion also matched expectations. No EPS figures were provided in the supplied guidance updates. * Neutral Sentiment: A Zacks comparison characterized ALHC as a potential value-stock candidate relative to PACS Group, but this represents an investment-screening view rather than a change in company fundamentals. PACS or ALHC: Which Is the Better Value Stock Right Now? * Negative Sentiment: Kaplan Fox, Lowey Dannenberg and Pomerantz announced investigations into potential federal securities-law violations. These announcements appear related to allegations concerning Alignment Healthcare and may increase legal, reputational and investor uncertainty; the investigations do not establish wrongdoing. Lowey Dannenberg Investigation Analysts set new price targets. Several equities research analysts have issued reports on ALHC shares. UBS Group restated a "neutral" rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. Weiss Ratings upgraded Alignment Healthcare from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Thursday, May 7th. Wall Street Zen raised Alignment Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Barclays cut their target price on Alignment Healthcare from $19.00 to $16.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 26th. Finally, Wolfe Research began coverage on Alignment Healthcare in a research report on Friday, April 17th. They set an "outperform" rating and a $24.00 price target on the stock. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Alignment Healthcare has a consensus rating of "Moderate Buy" and a consensus target price of $24.30. Insider activity at Alignment Healthcare. In related news, insider Hyong Kim sold 35,951 shares of the business's stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $19.86, for a total transaction of $713,986.86. Following the completion of the transaction, the insider directly owned 331,750 shares in the company, valued at $6,588,555. The trade was a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John E. Kao sold 298,000 shares of the company's stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $19.86, for a total value of $5,918,280.00. Following the completion of the transaction, the chief executive officer owned 1,088,766 shares in the company, valued at $21,622,892.76. This represents a 21.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,039,951 shares of company stock valued at $19,976,967 in the last ninety days. 5.20% of the stock is currently owned by corporate insiders. Institutional trading of Alignment Healthcare. A number of hedge funds have recently made changes to their positions in the stock. Summit Securities Group LLC bought a new stake in Alignment Healthcare in the 4th quarter worth approximately $26,000. Larson Financial Group LLC purchased a new stake in shares of Alignment Healthcare in the 3rd quarter valued at $33,000. Parallel Advisors LLC grew its holdings in shares of Alignment Healthcare by 87.7% during the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company's stock valued at $33,000 after purchasing an additional 773 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Alignment Healthcare during the 3rd quarter valued at $53,000. Finally, Wexford Capital LP purchased a new position in Alignment Healthcare in the 3rd quarter worth $164,000. 86.19% of the stock is owned by institutional investors. About Alignment Healthcare. Alignment Healthcare, Inc NASDAQ: ALHC is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience. At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Alignment Healthcare, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list. While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Trade Show News
Jul 28th, 2026
Securities fraud investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) following whistleblower lawsuit of Financial manipulation.

Securities fraud investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) following whistleblower lawsuit of Financial manipulation. LOS ANGELES-(BUSINESS WIRE)-Glancy Prongay Wolke & Rotter LLP today continues its investigation on behalf of Alignment Healthcare, Inc. ("Alignment" or the "Company") (NASDAQ: ALHC) investors concerning the Company's possible violations of the federal securities laws after the stock price fell 16% on July 8, 2026. What Happened? On July 8, 2026, reports emerged that a former Alignment executive had filed a whistleblower lawsuit alleging that the Company manipulated its finances to boost its stock price and executive compensation. The lawsuit, filed by the former chief transformation officer, alleges that Alignment deliberately misclassified $8 million to $10 million in routine operating expenses (such as routine software maintenance and production support) as capital expenditures within its technology sector, thereby artificially inflating the Company's adjusted EBITDA and enabling the Company to report its "first full year of positive adjusted EBITDA as a public company". On this news, Alignment's stock price fell $4.02, or 16.7%, to close at $20.03 per share on July 8, 2026, thereby injuring investors. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALIGNMENT HEALTHCARE, INC. (ALHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. About Glancy Prongay Wolke & Rotter LLP GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome. Contacts. Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit its website at: www.glancylaw.com. More News From Glancy Prongay Wolke & Rotter LLP LOS ANGELES-( BUSINESS WIRE )-Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Microvast Holdings, Inc. ("Microvast" or the "Company") (NASDAQ: MVST) common stock between April 1, 2025 and March 16, 2026, inclusive (the "Class Period"). Microvast investors have until September 21, 2026 to file a lead plaintiff motion. IF YOU SUFFE... LOS ANGELES-( BUSINESS WIRE )-Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC. (CAPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Wh... LOS ANGELES-( BUSINESS WIRE )-Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). PROCEPT investors have until September 22, 2026 to file a lead plaintiff motion.IF Y... Glancy Prongay Wolke & Rotter LLP. NASDAQ:ALHC Release Summary Whistleblower suit alleges Alignment misclassified $8-10M as capex to inflate EBITDA. Stock fell 16.7% to $20.03 on 7/8/26 news. Release Versions Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit its website at: www.glancylaw.com.

Southwest Medical Consulting
Jul 9th, 2026
Whistleblower lawsuit accuses Alignment of accounting fraud.

Whistleblower lawsuit accuses Alignment of accounting fraud. A former executive is claiming that the MA insurer recorded millions of dollars as capital expenditures that should have been operating expenses, inflating its value. Alignment strongly denied the allegations.